Abstract
Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.
Author supplied keywords
Cite
CITATION STYLE
Alberca, R. W., Andrade, M. M. de S., Branco, A. C. C. C., Pietrobon, A. J., Pereira, N. Z., Fernandes, I. G., … Sato, M. N. (2020). Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19. Frontiers in Medicine, 7. https://doi.org/10.3389/fmed.2020.580677
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
